ANTIVIRAL MECHANISMS OF 2-5A-DEPENDENT RNASE L
ANTIVIRAL MECHANISMS OF 2-5A-DEPENDENT RNASE L
批准号:
9761446
负责人:
Robert H. Silverman
金额:
$40.06万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-25 至 2022-08-31
关键词:
2-5A SynthetaseABCE1 geneADAR1Antiviral AgentsAntiviral ResponseApoptoticAutophagocytosisBindingBiological AssayCaspaseCause of DeathCell DeathCellsCleaved cellComplexCrystallizationDNA VirusesDouble-Stranded RNAEnhancersEnzymesEquilibriumFamilyHealthHost DefenseHumanImmune systemInflammasomeInflammationInflammatoryIntegration Host FactorsInterferonsKnockout MiceKnowledgeLeadMediatingMusOncolytic virusesPathogenicityPathway interactionsPharmaceutical PreparationsPhiladelphiaPopulationProtein KinaseProtocols documentationRNA VirusesRampReportingRibonucleasesRoentgen RaysRoleSignal TransductionSmall RNAStructureSystemTherapeuticToxic effectVertebratesViralVirusVirus Diseasesdimerimprovedin vivoinhibitor/antagonistknockout genemembernoveloligoadenylatepathogenic virusphosphodiesterase Vsmall moleculesmall molecule inhibitorviral RNA
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The 2',5'-oligoadenylate (2-5A) synthetase (OAS)-RNase L system is a robust interferon (IFN)-inducible
antiviral pathway that contributes to the survival of higher vertebrates against both RNA and DNA viruses.
Accordingly, viruses have acquired and evolved a multitude of mechanisms to antagonize OAS-RNase L.
During the past 5 years, we established roles for RNase L in IFN signaling, inflammasome activation and
autophagy. Yet there remains much to be learned about how RNase L suppresses viral infections, how viruses
evade these enzymes, and how the host recovers from RNase L activation. In particular, our knowledge of how
RNase L is regulated through its protein kinase-like domain, how RNase L mediates cell death from ADAR1
deficiency, how the RNase L inhibitor (ABCE1 aka RLI) functions, and how RNase L activates the NLRP3
inflammasome is still fragmentary. Therefore, the proposed continuation of this project will systematically
investigate the major outstanding questions about this critically important host antiviral pathway. The unifying
theme of this application concerns how RNase L function is regulated beyond its activation by 2-5A, in
particular through its protein kinase-like (PKL) domain, to control viral infections and inflammation. Our findings
lead to the hypothesis that the OAS-RNase L system is an integral part of the host immune system that must
be tightly regulated to eliminate viruses while also limiting its harmful pro-inflammatory effects. Our specific
aims are: (1) To study the impact of the RNase L PKL domain on cells and viruses we will evaluate recently
identified small molecule inhibitors, enhancers and their derivatives on RNase L activity, determine the ability
of the small molecules to control viral infections, and investigate effects of the RNase L inhibitors on cell death
caused by ADAR1 deficiency. (2) To investigate how the ATP-binding cassette member, ABCE1 (RLI), limits
RNase L activity, we will determine precisely how ABCE1 interacts with RNase L to inhibit its activity, establish
how the host cells ramps up RNase L activity during viral infections by caspase-mediated cleavage of ABCE1,
and determine the ability of ABCE1 to counteract cellular toxicity of double stranded RNA by inhibiting RNase L.
(3) To probe the mechanism of NLRP3 inflammasome activation by RNase L, we will identify and characterize
RNase L-cleaved viral RNA activators of the NLRP3 inflammasome, determine effects of the small RNA
cleavage products on inflammasome activation, and determine the impact of RNase L inhibitor drugs on viral
mediated inflammation in vivo. Viral infections remain a serious threat to human health worldwide. Despite viral
countermeasures, the OAS-RNase L system has a major impact against many types of pathogenic viruses.
These studies emphasize how central and important it is to regulate RNase L in order to mediate the balance
between antiviral activity and cell death. It is believed that a better understanding of the viral and host factors
that regulate RNase L activity may eventually lead to novel and improved therapeutic approaches for treating
established and emerging viral infections in the human population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ANTIVIRAL MECHANISMS OF 2-5A-DEPENDENT RNASE L
-
批准号:10005110
-
项目类别:
-
资助金额:$40.25万
-
财政年份:2017
-
负责人:Robert H. Silverman
-
依托单位:
Control of Viral Pathogenesis by Regulation of 2-5A Levels
-
批准号:8784188
-
项目类别:
-
资助金额:$71.33万
-
财政年份:2013
-
负责人:Robert H. Silverman
-
依托单位:
Control of Viral Pathogenesis by Regulation of 2-5A Levels
-
批准号:10077787
-
项目类别:
-
资助金额:$79.5万
-
财政年份:2013
-
负责人:Robert H. Silverman
-
依托单位:
Control of Viral Pathogenesis by Regulation of 2-5A Levels
-
批准号:8974219
-
项目类别:
-
资助金额:$71.33万
-
财政年份:2013
-
负责人:Robert H. Silverman
-
依托单位:
Control of Viral Pathogenesis by Regulation of 2-5A Levels
-
批准号:10310409
-
项目类别:
-
资助金额:$78.89万
-
财政年份:2013
-
负责人:Robert H. Silverman
-
依托单位:
Control of Viral Pathogenesis by Regulation of 2-5A Levels
-
批准号:8476886
-
项目类别:
-
资助金额:$71.6万
-
财政年份:2013
-
负责人:Robert H. Silverman
-
依托单位:
Control of Viral Pathogenesis by Regulation of 2-5A Levels
-
批准号:9191335
-
项目类别:
-
资助金额:$71.33万
-
财政年份:2013
-
负责人:Robert H. Silverman
-
依托单位:
Control of Viral Pathogenesis by Regulation of 2-5A Levels
-
批准号:10540316
-
项目类别:
-
资助金额:$78.86万
-
财政年份:2013
-
负责人:Robert H. Silverman
-
依托单位:
Control of Viral Pathogenesis by Regulation of 2-5A Levels
-
批准号:8601426
-
项目类别:
-
资助金额:$70.45万
-
财政年份:2013
-
负责人:Robert H. Silverman
-
依托单位:
AMPLIFICATION OF ANTIVIRAL INNATE IMMUNITY BY SUPPRESSOR OF VIRUS RNA (svRNA)
-
批准号:7936346
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:Robert H. Silverman
-
依托单位:
AMPLIFICATION OF ANTIVIRAL INNATE IMMUNITY BY SUPPRESSOR OF VIRUS RNA (svRNA)
-
批准号:7809421
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:Robert H. Silverman
-
依托单位:
Broad Spectrum Antivirals Against Biodefense Select Agents That Activate RNase L
-
批准号:7641948
-
项目类别:
-
资助金额:$34.51万
-
财政年份:2008
-
负责人:Robert H. Silverman
-
依托单位:
THE PREVALANCE OF DIABETES AMONG EMERGENCY DEPARTMENT PATIENTS WITH NO PREVIOUS
-
批准号:7608242
-
项目类别:
-
资助金额:$69.45万
-
财政年份:2007
-
负责人:Robert H. Silverman
-
依托单位:
STRESS HYPERGLYCEMIA IN EMERGENCY DEPARTMENT (ED) PATIENTS: A NORMAL RESPONSE
-
批准号:7377126
-
项目类别:
-
资助金额:$69.72万
-
财政年份:2006
-
负责人:Robert H. Silverman
-
依托单位:
STRESS HYPERGLYCEMIA IN EMERGENCY DEPARTMENT (ED) PATIENTS: A NORMAL RESPONSE
-
批准号:7203207
-
项目类别:
-
资助金额:$16.87万
-
财政年份:2005
-
负责人:Robert H. Silverman
-
依托单位:
Role of RNase L in the Biology of Prostate Cancer
-
批准号:7340175
-
项目类别:
-
资助金额:$29.74万
-
财政年份:2004
-
负责人:Robert H. Silverman
-
依托单位:
Role of RNase L in the Biology of Prostate Cancer
-
批准号:6703242
-
项目类别:
-
资助金额:$31.37万
-
财政年份:2004
-
负责人:Robert H. Silverman
-
依托单位:
Role of RNase L in the Biology of Prostate Cancer
-
批准号:7008850
-
项目类别:
-
资助金额:$30.63万
-
财政年份:2004
-
负责人:Robert H. Silverman
-
依托单位:
Role of RNase L in the Biology of Prostate Cancer
-
批准号:6856518
-
项目类别:
-
资助金额:$31.37万
-
财政年份:2004
-
负责人:Robert H. Silverman
-
依托单位:
Role of RNase L in the Biology of Prostate Cancer
-
批准号:7171854
-
项目类别:
-
资助金额:$29.74万
-
财政年份:2004
-
负责人:Robert H. Silverman
-
依托单位: